Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:RPRX's Cash-to-Debt is ranked higher than
98% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. NAS:RPRX: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:RPRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.07  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.30
NAS:RPRX's Equity-to-Asset is ranked higher than
64% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:RPRX: 0.30 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:RPRX' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.6  Med: 0.91 Max: 0.99
Current: 0.3
-1.6
0.99
Interest Coverage No Debt
NAS:RPRX's Interest Coverage is ranked higher than
98% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:RPRX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:RPRX' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: -93.32
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -48257.89
NAS:RPRX's Operating Margin % is ranked lower than
98% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. NAS:RPRX: -48257.89 )
Ranked among companies with meaningful Operating Margin % only.
NAS:RPRX' s Operating Margin % Range Over the Past 10 Years
Min: -631466.67  Med: -151066.44 Max: -908.49
Current: -48257.89
-631466.67
-908.49
Net Margin % -48257.89
NAS:RPRX's Net Margin % is ranked lower than
98% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. NAS:RPRX: -48257.89 )
Ranked among companies with meaningful Net Margin % only.
NAS:RPRX' s Net Margin % Range Over the Past 10 Years
Min: -631466.67  Med: -151066.44 Max: -908.49
Current: -48257.89
-631466.67
-908.49
ROE % -224.76
NAS:RPRX's ROE % is ranked lower than
86% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. NAS:RPRX: -224.76 )
Ranked among companies with meaningful ROE % only.
NAS:RPRX' s ROE % Range Over the Past 10 Years
Min: -336.72  Med: -131.92 Max: -55.84
Current: -224.76
-336.72
-55.84
ROA % -170.09
NAS:RPRX's ROA % is ranked lower than
87% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. NAS:RPRX: -170.09 )
Ranked among companies with meaningful ROA % only.
NAS:RPRX' s ROA % Range Over the Past 10 Years
Min: -237.27  Med: -107.32 Max: -52.9
Current: -170.09
-237.27
-52.9
ROC (Joel Greenblatt) % -458450.00
NAS:RPRX's ROC (Joel Greenblatt) % is ranked lower than
99% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. NAS:RPRX: -458450.00 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:RPRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -458450  Med: -64009.21 Max: -24464.29
Current: -458450
-458450
-24464.29
3-Year EBITDA Growth Rate -20.00
NAS:RPRX's 3-Year EBITDA Growth Rate is ranked higher than
50% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. NAS:RPRX: -20.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:RPRX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -51.7  Med: 6 Max: 68.8
Current: -20
-51.7
68.8
3-Year EPS without NRI Growth Rate -20.10
NAS:RPRX's 3-Year EPS without NRI Growth Rate is ranked higher than
52% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. NAS:RPRX: -20.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:RPRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -59.2  Med: 5.25 Max: 113.7
Current: -20.1
-59.2
113.7
GuruFocus has detected 2 Warning Signs with Repros Therapeutics Inc $NAS:RPRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:RPRX's 30-Y Financials

Financials (Next Earnings Date: 2017-08-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

RPRX Guru Trades in Q2 2016

Jim Simons 561,713 sh (+216.08%)
» More
Q3 2016

RPRX Guru Trades in Q3 2016

Charles Brandes 18,000 sh (New)
Jim Simons 667,113 sh (+18.76%)
» More
Q4 2016

RPRX Guru Trades in Q4 2016

Jim Simons 716,413 sh (+7.39%)
Charles Brandes Sold Out
» More
Q1 2017

RPRX Guru Trades in Q1 2017

Jim Simons 727,113 sh (+1.49%)
» More
» Details

Insider Trades

Latest Guru Trades with RPRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:KTOV, OTCPK:CDXI, OTCPK:BLUSF, OTCPK:RGIN, OTCPK:CRYO, OTCPK:ENUM, NAS:TENX, NAS:CLSN, OTCBB:DDRT, OTCPK:MATN, NAS:SNGX, AMEX:HEB, NAS:MBRX, OTCPK:OPNT, NAS:XTLB, NAS:GNVC, NAS:ANTH, NAS:PZRX, OTCPK:BCTXF, NAS:SBOT » details
Traded in other countries:ZONN.Germany,
Headquarter Location:USA
Repros Therapeutics Inc is a development stage biopharmaceutical company. The Company is engaged in the development of new drugs to treat hormonal and reproductive system disorders.

Repros Therapeutics Inc was organized on August 20, 1987. The Company is a development stage biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company's main product candidate, Androxal, is a single isomer of clomiphene citrate and is an orally active proprietary small molecule compound. It is developing Androxal for men of reproductive age with low testosterone levels. Androxal treats the underlying mechanism that causes secondary hypogonadism and restores normal testicular function. The Company's second product candidate, Proellex for female reproductive health, is a new chemical entity that acts as a selective blocker of the progesterone receptor and is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis. The Company recently completed a low dose study to demonstrate both safety and signals of efficacy in low oral doses of Proellex. The Company's research and development activities, preclinical studies and clinical trials, and the manufacturing, marketing and labeling of any products it may develop, are subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries.

Ratios

vs
industry
vs
history
PB Ratio 8.71
RPRX's PB Ratio is ranked higher than
51% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. RPRX: 8.71 )
Ranked among companies with meaningful PB Ratio only.
RPRX' s PB Ratio Range Over the Past 10 Years
Min: 1.54  Med: 13.87 Max: 165.08
Current: 8.71
1.54
165.08
EV-to-EBIT -0.60
RPRX's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. RPRX: -0.60 )
Ranked among companies with meaningful EV-to-EBIT only.
RPRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -31.1  Med: -5.2 Max: -0.2
Current: -0.6
-31.1
-0.2
EV-to-EBITDA -0.60
RPRX's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. RPRX: -0.60 )
Ranked among companies with meaningful EV-to-EBITDA only.
RPRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -31.5  Med: -5.2 Max: -0.2
Current: -0.6
-31.5
-0.2
Current Ratio 1.57
RPRX's Current Ratio is ranked higher than
55% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. RPRX: 1.57 )
Ranked among companies with meaningful Current Ratio only.
RPRX' s Current Ratio Range Over the Past 10 Years
Min: 0.23  Med: 8.91 Max: 66.45
Current: 1.57
0.23
66.45
Quick Ratio 1.57
RPRX's Quick Ratio is ranked higher than
56% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. RPRX: 1.57 )
Ranked among companies with meaningful Quick Ratio only.
RPRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.23  Med: 8.1 Max: 66.45
Current: 1.57
0.23
66.45

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.90
RPRX's 3-Year Average Share Buyback Ratio is ranked lower than
54% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. RPRX: -3.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RPRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -48.3  Med: -20.5 Max: 23.9
Current: -3.9
-48.3
23.9

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 18.00
RPRX's Price-to-Net-Current-Asset-Value is ranked higher than
70% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. RPRX: 18.00 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
RPRX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0  Med: 5.32 Max: 224.36
Current: 18
0
224.36
Price-to-Tangible-Book 9.00
RPRX's Price-to-Tangible-Book is ranked higher than
58% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. RPRX: 9.00 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
RPRX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.42  Med: 5.24 Max: 152.17
Current: 9
0.42
152.17
Price-to-Median-PS-Value 1.35
RPRX's Price-to-Median-PS-Value is ranked lower than
78% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. RPRX: 1.35 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
RPRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 0.08 Max: 75.68
Current: 1.35
0
75.68
Earnings Yield (Greenblatt) % -166.03
RPRX's Earnings Yield (Greenblatt) % is ranked lower than
98% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. RPRX: -166.03 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
RPRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -5792.99  Med: 464.5 Max: 41501.3
Current: -166.03
-5792.99
41501.3

More Statistics

Revenue (TTM) (Mil) $0.04
EPS (TTM) $ -0.72
Beta0.61
Short Percentage of Float2.04%
52-Week Range $0.51 - 2.48
Shares Outstanding (Mil)26.73

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 0 0
EPS ($) -0.54 -0.91
EPS without NRI ($) -0.54 -0.91
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:RPRX

Headlines

Articles On GuruFocus.com
Repros Therapeutics Inc.® Reports First Quarter 2017 Financial Results May 09 2017 
Repros Announces the Issuance of New U.S. Patent Relating to Treatment Using Off Drug Intervals For Apr 17 2017 
Repros Names Larry Dillaha, M.D., its Permanent President and CEO Apr 10 2017 
Company Holds Meeting with FDA to Discuss Oral Proellex® in the Treatment of Uterine Fibroids Apr 10 2017 
Repros Therapeutics Inc.® Reports Fourth Quarter and Year End 2016 Financial Results Mar 31 2017 
Weekly CFO Buys Highlight: RPRX, ARCT, LUB, JCS, DCIN Apr 23 2012 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 10 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 09 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) May 10 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 09 2009 

More From Other Websites
Repros Announces Pricing of $3.0 Million Public Offering Of Common Stock And Warrants To Purchase... May 18 2017
Repros Announces Proposed Public Offering Of Common Stock And Warrants To Purchase Common Stock May 17 2017
Repros Therapeutics reports 1Q loss May 09 2017
Repros Therapeutics Inc.® Reports First Quarter 2017 Financial Results May 09 2017
What's in the Cards for Repros (RPRX) this Earnings Season? May 05 2017
Repros Announces the Issuance of New U.S. Patent Relating to Treatment Using Off Drug Intervals For... Apr 17 2017
Repros' Proellex Continues to be Under Partial Clinical Hold Apr 11 2017
Woodlands drug company names new top exec Apr 11 2017
Repros Therapeutics stock halted after FDA says partial clinical hold will continue for fibroids... Apr 10 2017
Repros Names Larry Dillaha, M.D., its Permanent President and CEO Apr 10 2017
Company Holds Meeting with FDA to Discuss Oral Proellex® in the Treatment of Uterine Fibroids Apr 10 2017
Repros Therapeutics Inc.® Reports Fourth Quarter and Year End 2016 Financial Results Mar 31 2017
Repros (RPRX) Q4 Earnings: What's in Store for the Stock? Mar 07 2017
Repros to Meet with the FDA for Phase III Proellex Program Dec 13 2016
How Bonanza Creek Energy Inc (BCEI) Stacks Up In Relation to Its Peers Dec 13 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)